Base de dados : MEDLINE
Pesquisa : E07.935 [Categoria DeCS]
Referências encontradas : 837 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 84 ir para página                         

  1 / 837 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29262509
[Au] Autor:Zhou Q; Zuo MH; Li QW; Tian YT; Xie YB; Wang YB; Yang GY; Ye YJ; Guo P; Liu JP; Liu ZL; An C; Zhou T; Tian Z; Liu CB; Hu Y; Chi XY; Shen Y; Xia Y; Hu KW
[Ad] Endereço:Department of Oncology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, China.
[Ti] Título:[Efficacy of Weitan Waifu patch on the postsurgical gastroparesis syndrome of gastrointestinal cancer: a multi-center trial].
[So] Source:Zhonghua Zhong Liu Za Zhi;39(12):919-925, 2017 Dec 23.
[Is] ISSN:0253-3766
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:To investigate the safety and efficacy of the Weitan Waifu patch on the postsurgical gastroparesis syndrome (PGS) of gastrointestinal cancer. The multi-center, double-blind, randomized controlled trial was conducted with superiority design. Patients with PGS of gastrointestinal cancer diagnosed in 4 AAA hospitals and the abdominal symptom manifested as cold syndrome by Chinese local syndrome differentiation were recruited. These patients were randomly divided into two groups according to 1∶1 proportion. Placebo or Weitan Waifu patch was applied in control group or intervention group, respectively, based on the basic treatments, including nutrition support, gastrointestinal decompression, promoting gastric dynamics medicine.Two acupuncture points (Zhongwan and Shenque) were stuck with placebo in control group or patch in treatment group. The intervention course was 14 days or reached the effective standard. From July 15, 2013 to Jun 3, 2015, 128 participants were recruited and 120 eligible cases were included in the full analysis set (FAS), and 60 cases in each group. 88 cases were included in the per-protocol set (PPS), including 45 cases in the treatment group and 43 cases in the control group. In the FAS, the clinical effective rate in the treatment group was 68.3%, significantly superior than 41.7% of the control group ( =0.003). The medium time of effective therapy in the treatment group was 8 days, significantly shorter than 10 days in the control group ( =0.017). In the FAS, 3 adverse events occurred in the treatment group, including mild to moderate decrustation, pruritus and nausea. The incidence rate of adverse events was 5.0% (3/60) and these symptoms were spontaneously remitted after drug withdrawal. No severe adverse events were observed in the control group. There was no significant difference between these two groups ( =0.244). Weitan Waifu patch is a safely and effectively therapeutic method for patients with PGS (cold syndrome) of gastroenterological cancer. International Standard Randomized Controlled Trial Number Register, ISRCTN18291857.
[Mh] Termos MeSH primário: Medicamentos de Ervas Chinesas/uso terapêutico
Neoplasias Gastrointestinais/cirurgia
Gastroparesia/tratamento farmacológico
Complicações Pós-Operatórias/tratamento farmacológico
Adesivo Transdérmico
[Mh] Termos MeSH secundário: Pontos de Acupuntura
Método Duplo-Cego
Seres Humanos
Síndrome
Adesivo Transdérmico/efeitos adversos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Drugs, Chinese Herbal)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180205
[Lr] Data última revisão:
180205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171221
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0253-3766.2017.12.008


  2 / 837 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28467333
[Au] Autor:Inchingolo F; Vermesan D; Inchingolo AD; Malcangi G; Santacroce L; Scacco S; Benagiano V; Girolamo F; Cagiano R; Caprio M; Longo L; Abbinante A; Inchingolo AM; Dipalma G; Tarullo A; Tattoli M
[Ti] Título:Bedsores successfully treated with topical phenytoin.
[So] Source:Acta Biomed;88(1):45-48, 2017 04 28.
[Is] ISSN:0392-4203
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:Phenytoin is normally used in epilepsy treatment. One of the side effect affecting a significative part of the treated patients is the gingival overgrowth. It could surely be a correlation between this stimulatory effect and the assessment of phenytoin in wound healing. In fact, some studies of the literature have shown that topical phenytoin promotes healing of traumatic wounds, burns and ulcers by decubitus or stasis (diabetic or venous) and we emphasize, in vitiligo, a particular attention into repigmentation. The related mechanism of action seems to be multifactorial. In the present paper topical phenytoin has been used as wound-healing agent in 19 documented cases of bedsores, divided in treated and placebo group. The used concentration of phenytoin was 5 mg/L dissolved in a water solution of 9 g NaCl /L (0.9% P/V of NaCl). Patches soaked with phenytoin solution were applied over the bedsores along 3 hours every 12 hours. Results showed that phenytoin treated patients healed their wounds significantly before (p<0.001) with respect to controls.
[Mh] Termos MeSH primário: Fármacos Dermatológicos/uso terapêutico
Fenitoína/uso terapêutico
Lesão por Pressão/tratamento farmacológico
Adesivo Transdérmico
[Mh] Termos MeSH secundário: Administração Tópica
Idoso
Idoso de 80 Anos ou mais
Feminino
Seres Humanos
Masculino
Meia-Idade
Cicatrização
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Dermatologic Agents); 6158TKW0C5 (Phenytoin)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180125
[Lr] Data última revisão:
180125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.23750/abm.v88i1.5794


  3 / 837 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28858835
[Au] Autor:Rajabalaya R; Mun CY; Chellian J; Chakravarthi S; David SR
[Ad] Endereço:.
[Ti] Título:Transdermal delivery of tolterodine tartrate for overactive bladder treatment: In vitro and in vivo evaluation.
[So] Source:Acta Pharm;67(3):325-339, 2017 Sep 01.
[Is] ISSN:1846-9558
[Cp] País de publicação:Croatia
[La] Idioma:eng
[Ab] Resumo:The purpose of the study was to develop a transdermal tolterodine tartrate (TT) patch and to analyse its efficacy for overactive bladder (OAB) treatment. Patches were prepared using various polymers and plasticizers via the solvent casting method. The patches were characterized for tensile strength, thickness, moisture content, modulus of elasticity and water absorption capacity. Differential scanning calorimetry and Fourier transform infrared analyses were also performed. To determine patch effectiveness, in vitro release, permeation and animal studies were performed. The patches showed satisfactory percentage of release, up to 89.9 %, and their mechanical properties included thickness (0.10-0.15 mm), tensile strength (4.62-9.98 MPa) and modulus of elasticity (20-29 MPa). There were no significant interactions between TT and other excipients. Animal studies indicated that the TT patch reduced the incidence of side effects; however, studies of longer duration are required to determine the effectiveness in treating OAB.
[Mh] Termos MeSH primário: Tartarato de Tolterodina/administração & dosagem
Adesivo Transdérmico
Bexiga Urinária Hiperativa/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Cutânea
Animais
Masculino
Ratos Sprague-Dawley
Absorção Cutânea
Tartarato de Tolterodina/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
5T619TQR3R (Tolterodine Tartrate)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171030
[Lr] Data última revisão:
171030
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170901
[St] Status:MEDLINE


  4 / 837 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28787488
[Au] Autor:Abbasi J
[Ti] Título:Flu Vaccine Patch in Development.
[So] Source:JAMA;318(6):510, 2017 Aug 08.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Vacinas contra Influenza/administração & dosagem
Adesivo Transdérmico
[Mh] Termos MeSH secundário: Seres Humanos
Autoadministração
[Pt] Tipo de publicação:NEWS
[Nm] Nome de substância:
0 (Influenza Vaccines)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170920
[Lr] Data última revisão:
170920
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170809
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.9886


  5 / 837 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28786987
[Au] Autor:Park KW; Kim EJ; Han HJ; Shim YS; Kwon JC; Ku BD; Park KH; Yi HA; Kim KK; Yang DW; Lee HW; Kang H; Kwon OD; Kim S; Lee JH; Chung EJ; Park SW; Park MY; Yoon B; Kim BC; Seo SW; Choi SH
[Ad] Endereço:Department of Neurology, Cognitive Disorders and Dementia Center, Dong-A University College of Medicine and Institute of Convergence Bio-Health, Busan, South Korea.
[Ti] Título:Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer's dementia associated with minimal and moderate ischemic white matter hyperintensities: A multicenter prospective open-label clinical trial.
[So] Source:PLoS One;12(8):e0182123, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND OBJECTIVE: Studies investigating the impact of white matter hyperintensities (WMHs) on the response of acetylcholinesterase inhibitors in patients with Alzheimer's disease (AD) have presented inconsistent results. We aimed to compare the effects of the rivastigmine patch between patients with AD with minimal WMHs and those with moderate WMHs. METHODS: Three hundred patients with mild to moderate AD were enrolled in this multicenter prospective open-label study and divided into two groups. Group 1 comprised patients with AD with minimal WMHs and group 2 comprised those with moderate WMHs. The patients were treated with a rivastigmine patch for 24 weeks. Efficacy measures were obtained at baseline and after 24 weeks. The primary endpoint was the change in the AD Assessment Scale-Cognitive subscale (ADAS-Cog) from the baseline to the end of the study. RESULTS: Of the 300 patients, there were 206 patients in group 1 and 94 patients in group 2. The intention-to-treat group comprised 198 patients (group 1, n = 136; group 2, n = 46) during the 24-week study period. Demographic factors did not differ between group 1 and group 2. There were no significant differences in change in ADAS-cog between group 1 (-0.62±5.70) and group 2 (-0.23±5.98) after the 24-week rivastigmine patch therapy (p = 0.378). The patients in group 1 had a 0.63-point improvement from baseline on the Frontal Assessment Battery, while group 2 had a 0.16-point decline compared to baseline at the end of the study (p = 0.037). The rates of adverse events (AEs) (42.6 vs. 40.3%) and discontinuation due to AEs (10.3% vs. 4.3%) did not differ between the groups. CONCLUSIONS: Although the efficacy and tolerability of rivastigmine patch therapy were not associated with WMH severity in patients with AD, some improvement in frontal function was observed in those with minimal WMHs. TRIAL REGISTRATION: ClinicalTrials.gov NCT01380288.
[Mh] Termos MeSH primário: Doença de Alzheimer/diagnóstico por imagem
Doença de Alzheimer/tratamento farmacológico
Inibidores da Colinesterase/administração & dosagem
Fármacos Neuroprotetores/administração & dosagem
Rivastigmina/administração & dosagem
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Encéfalo/diagnóstico por imagem
Encéfalo/efeitos dos fármacos
Inibidores da Colinesterase/efeitos adversos
Feminino
Seres Humanos
Masculino
Meia-Idade
Fármacos Neuroprotetores/efeitos adversos
República da Coreia
Rivastigmina/efeitos adversos
Índice de Gravidade de Doença
Adesivo Transdérmico
Resultado do Tratamento
Substância Branca/diagnóstico por imagem
Substância Branca/efeitos dos fármacos
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Cholinesterase Inhibitors); 0 (Neuroprotective Agents); PKI06M3IW0 (Rivastigmine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171004
[Lr] Data última revisão:
171004
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170809
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0182123


  6 / 837 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28697832
[Au] Autor:Guo JM; Shi XX; Yang SW; Qian QF; Huang Y; Xie YQ; Ou P
[Ad] Endereço:Fujian Provincial Maternity and Children's Hospital of Fujian Medical University, Fuzhou, Fujian 350001, China. eve1019@126.com.
[Ti] Título:[Efficacy of clonidine transdermal patch in treatment of moderate to severe tic disorders in children].
[So] Source:Zhongguo Dang Dai Er Ke Za Zhi;19(7):786-789, 2017 Jul.
[Is] ISSN:1008-8830
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:OBJECTIVE: To investigate the difference in the efficacy between clonidine transdermal patch and haloperidol tablets in the treatment of moderate to severe tic disorders in children. METHODS: A total of 134 children with moderate to severe tic disorders were randomly divided into clonidine group (n=70) and haloperidol group (n=64). The clonidine and haloperidol groups were treated with clonidine transdermal patch and haloperidol tablets respectively, and the treatment lasted for 8 weeks in both groups. The Yale Global Tic Severity Scale (YGTSS) was used to evaluate the conditions of the children before and after treatment, and the adverse events during the treatment were recorded. RESULTS: The haloperidol group had a significantly better treatment outcome than the clonidine group after one week of treatment (P<0.05); the treatment outcome showed no significant difference between the two groups after 3, 5, and 8 weeks of treatment (P>0.05). The clonidine group had significantly less reductions in the motor tics, vocal tics, and function impairment scores and total score of YGTSS than the haloperidol group after one week of treatment (P<0.05); there were no significant differences in YGTSS score reductions between the two groups after 3, 5, and 8 weeks of treatment (P>0.05). The clonidine group had a significantly lower overall incidence of adverse events than the haloperidol group (8% vs 37%; P<0.01). CONCLUSIONS: Clonidine transdermal patch and haloperidol are both effective in the treatment of moderate to severe tic disorders in children. The clonidine transdermal patch, despite slow action, has comparable efficacy and fewer adverse effects compared with haloperidol.
[Mh] Termos MeSH primário: Clonidina/administração & dosagem
Transtornos de Tique/tratamento farmacológico
Adesivo Transdérmico
[Mh] Termos MeSH secundário: Criança
Pré-Escolar
Feminino
Haloperidol/uso terapêutico
Seres Humanos
Masculino
Índice de Gravidade de Doença
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
J6292F8L3D (Haloperidol); MN3L5RMN02 (Clonidine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171026
[Lr] Data última revisão:
171026
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170713
[St] Status:MEDLINE


  7 / 837 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28617467
[Au] Autor:Baik S; Kim DW; Park Y; Lee TJ; Ho Bhang S; Pang C
[Ad] Endereço:School of Chemical Engineering, Sungkyunkwan University, Suwon, Kyunggi-do 16419, South Korea.
[Ti] Título:A wet-tolerant adhesive patch inspired by protuberances in suction cups of octopi.
[So] Source:Nature;546(7658):396-400, 2017 06 14.
[Is] ISSN:1476-4687
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Adhesion strategies that rely on mechanical interlocking or molecular attractions between surfaces can suffer when coming into contact with liquids. Thus far, artificial wet and dry adhesives have included hierarchical mushroom-shaped or porous structures that allow suction or capillarity, supramolecular structures comprising nanoparticles, and chemistry-based attractants that use various protein polyelectrolytes. However, it is challenging to develop adhesives that are simple to make and also perform well-and repeatedly-under both wet and dry conditions, while avoiding non-chemical contamination on the adhered surfaces. Here we present an artificial, biologically inspired, reversible wet/dry adhesion system that is based on the dome-like protuberances found in the suction cups of octopi. To mimic the architecture of these protuberances, we use a simple, solution-based, air-trap technique that involves fabricating a patterned structure as a polymeric master, and using it to produce a reversed architecture, without any sophisticated chemical syntheses or surface modifications. The micrometre-scale domes in our artificial adhesive enhance the suction stress. This octopus-inspired system exhibits strong, reversible, highly repeatable adhesion to silicon wafers, glass, and rough skin surfaces under various conditions (dry, moist, under water and under oil). To demonstrate a potential application, we also used our adhesive to transport a large silicon wafer in air and under water without any resulting surface contamination.
[Mh] Termos MeSH primário: Adesividade
Adesivos/química
Materiais Biomiméticos/química
Octopodiformes/anatomia & histologia
Polímeros/química
Adesivo Transdérmico
Molhabilidade
[Mh] Termos MeSH secundário: Animais
Biomimética
Pele
Suínos
Água/química
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Adhesives); 0 (Polymers); 059QF0KO0R (Water)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171027
[Lr] Data última revisão:
171027
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170616
[St] Status:MEDLINE
[do] DOI:10.1038/nature22382


  8 / 837 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28594244
[Au] Autor:Suzuki Y; Kamijo Y; Yoshizawa T; Fujita Y; Usui K; Kishino T
[Ad] Endereço:a Emergency Medical Center and Poison Center , Saitama Medical University Hospital , Saitama , Japan.
[Ti] Título:Acute cholinergic syndrome in a patient with mild Alzheimer's type dementia who had applied a large number of rivastigmine transdermal patches on her body.
[So] Source:Clin Toxicol (Phila);55(9):1008-1010, 2017 Nov.
[Is] ISSN:1556-9519
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:CASE PRESENTATION: A 91-year-old woman was transferred to our Emergency Medical Center and Poison Center with somnolence, hypertension (186/61 mm Hg), and repeated vomiting. Three hours later, 10 transdermal patches, each containing 18 mg of rivastigmine (9.5 mg/24 h), were found on her lower back and both thighs, when miosis, facial and trunk sweating, enhanced bowel sound, hypertension, and sinus tachycardia were noted. She was diagnosed with acute cholinergic syndrome due to rivastigmine poisoning. Her hypertension and sinus tachycardia peaked 8 and 5 h after all the patches were removed, respectively. Her symptoms subsided spontaneously after 17 h. DISCUSSION: In the present case, our patient was presented with acute cholinergic syndrome due to carbamate intoxication after massive transdermal exposure to rivastigmine. Toxicological analysis revealed a remarkably high estimated serum rivastigmine concentration (150.6 ng/ml) and notably low serum butyrylcholinesterase activity (35 IU/l) on admission, with a markedly prolonged calculated elimination half-life of 6.5 h. CONCLUSIONS: Emergency physicians should consider acetylcholinesterase inhibitor exposure (e.g., rivastigmine) when patients are present with acute cholinergic syndrome.
[Mh] Termos MeSH primário: Doença de Alzheimer/tratamento farmacológico
Inibidores da Colinesterase/envenenamento
Frequência Cardíaca/efeitos dos fármacos
Hipertensão/induzido quimicamente
Síndromes Neurotóxicas/etiologia
Rivastigmina/envenenamento
Taquicardia Sinusal/induzido quimicamente
[Mh] Termos MeSH secundário: Administração Cutânea
Idoso de 80 Anos ou mais
Doença de Alzheimer/diagnóstico
Doença de Alzheimer/psicologia
Pressão Sanguínea/efeitos dos fármacos
Inibidores da Colinesterase/administração & dosagem
Overdose de Drogas
Feminino
Seres Humanos
Hipertensão/diagnóstico
Hipertensão/fisiopatologia
Síndromes Neurotóxicas/diagnóstico
Síndromes Neurotóxicas/fisiopatologia
Rivastigmina/administração & dosagem
Índice de Gravidade de Doença
Taquicardia Sinusal/diagnóstico
Taquicardia Sinusal/fisiopatologia
Adesivo Transdérmico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cholinesterase Inhibitors); PKI06M3IW0 (Rivastigmine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170911
[Lr] Data última revisão:
170911
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170609
[St] Status:MEDLINE
[do] DOI:10.1080/15563650.2017.1329536


  9 / 837 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28552053
[Au] Autor:Li J; Zeng M; Shan H; Tong C
[Ad] Endereço:College of Animal Science and Veterinary Medicine, Qingdao Agricultural University, Qingdao, 266109, China.
[Ti] Título:Microneedle Patches as Drug and Vaccine Delivery Platform.
[So] Source:Curr Med Chem;24(22):2413-2422, 2017.
[Is] ISSN:1875-533X
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Transcutaneous delivery is the ideal method for delivering therapeutic reagents or vaccines into skin. With their promise of self-administration, cost-effective and high efficiency, microneedle patches have been studied intensively as therapeutic and vaccination delivery platform that replaces injection by syringe. This review aims to summarize the recent advancements of microneedle patches in application for drugs and vaccine delivery. METHODS: We reviewed the most of recently published papers on microneedle patches, summarized their evolution, classification, state-of the-art capabilities and discussed promising application in drugs and vaccine delivery. RESULTS: With the rapid development of nanotechnology, microneedle patches have been improved by switching from undissolving to dissolving microneedles, and their safety has also improved dramatically. As a drug delivery tool, microneedle patches can deliver bioactive molecular of different physical size. Additionally, microneedle patches can be coated or encapsulate with DNA vaccine, subunit antigen, inactivated or live virus vaccine. Combining clinical results with the results of patient interview, microneedle patches are found to be feasible and are predicated to soon be acceptable for the medical service. CONCLUSION: In this review, we summarized the evolution, current and future application of microneedle patches as delivery vehicle for drugs and vaccines. Compared with traditional delivery tools, microneedle patches have many advantages, such as providing pain-free, non-invasive, convenient route for reagent administration and delivery, with no cold chain required for storage and transportation as well as decreasing sharp medical waste, needle-caused injury and transmission of blood-borne infectious disease in rural area. However, even though there are dramatic progress in preclinical investigation of microneedle patches, further testing will be required for clinical application. Further research should be implemented in multiple fields, such as vaccinology, immunology, and materials science, to improve this delivery platform. Because of their advantages in dose sparing, safety and treatment compliance, microneedle patches are expected to be widely applied in clinical treatment and vaccine administration in near future.
[Mh] Termos MeSH primário: Sistemas de Liberação de Medicamentos
Agulhas
Adesivo Transdérmico
Vacinas/administração & dosagem
[Mh] Termos MeSH secundário: Animais
Seres Humanos
Nanotecnologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Vaccines)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170912
[Lr] Data última revisão:
170912
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170530
[St] Status:MEDLINE
[do] DOI:10.2174/0929867324666170526124053


  10 / 837 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28514299
[Au] Autor:Tang J; Fan J; Yao Y; Cai W; Yin G; Zhou W
[Ad] Endereço:Department of Orthopaedic, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
[Ti] Título:Application of a buprenorphine transdermal patch for the perioperative analgesia in patients who underwent simple lumbar discectomy.
[So] Source:Medicine (Baltimore);96(20):e6844, 2017 May.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:This study aimed to investigate the perioperative analgesic effect of a buprenorphine transdermal patch in patients who underwent simple lumbar discectomy.In total, 96 patients were randomly divided into parecoxib intravenous injection (Group A), oral celecoxib (Group B), and buprenorphine transdermal patch groups (Group C). The pain status, degree of satisfaction, adverse effects, and condition in which the patient received tramadol hydrochloride for uncontrolled pain were recorded on the night before surgery, postoperative day 1, postoperative day 3, and postoperative day 5.The degree of patient satisfaction in Group C was higher than that in Groups A and B, with minimal adverse effects.The buprenorphine transdermal patch had a better perioperative analgesic effect in patients who underwent simple lumbar discectomy.
[Mh] Termos MeSH primário: Analgésicos Opioides/administração & dosagem
Buprenorfina/administração & dosagem
Discotomia
Vértebras Lombares/cirurgia
Assistência Perioperatória
Adesivo Transdérmico
[Mh] Termos MeSH secundário: Administração Cutânea
Administração Intravenosa
Administração Oral
Analgésicos Opioides/efeitos adversos
Buprenorfina/efeitos adversos
Celecoxib/administração & dosagem
Inibidores de Ciclo-Oxigenase 2/administração & dosagem
Discotomia/efeitos adversos
Feminino
Seres Humanos
Isoxazóis/administração & dosagem
Masculino
Meia-Idade
Medição da Dor
Dor Pós-Operatória/tratamento farmacológico
Satisfação do Paciente
Assistência Perioperatória/efeitos adversos
Tramadol/administração & dosagem
Adesivo Transdérmico/efeitos adversos
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Analgesics, Opioid); 0 (Cyclooxygenase 2 Inhibitors); 0 (Isoxazoles); 39J1LGJ30J (Tramadol); 40D3SCR4GZ (Buprenorphine); 9TUW81Y3CE (parecoxib); JCX84Q7J1L (Celecoxib)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170613
[Lr] Data última revisão:
170613
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170518
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000006844



página 1 de 84 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde